Show simple item record

dc.contributor.authorRangaswamy, G
dc.contributor.authorIbrahim, N
dc.contributor.authorThirion, P
dc.date.accessioned2011-11-21T08:46:54Z
dc.date.available2011-11-21T08:46:54Z
dc.date.issued2011-10
dc.identifier.citation2011, 45 (41) : 48 Irish Medical Timesen
dc.identifier.urihttp://hdl.handle.net/10147/190069
dc.descriptionA team from the Radiation Oncology Department at St. Luke's Hospital, Dublin, present a case of high risk localised adenocarcinoma of the prostate and discuss the role of leuprorelin acetate (Eligard) in the management of a caseen
dc.language.isoenen
dc.subjectPROSTATE CANCERen
dc.titleAssessing the role of long-term LHRH agonist (Eligard 45mg) in managing localised prostatic adenocarcinomaen
dc.typeArticleen
dc.typeOtheren
dc.contributor.departmentDeparment of Radiation Oncology, St. Luke's Hospital, Dublin 6.en


This item appears in the following Collection(s)

Show simple item record